Early Phase 1
N=11
EEG Characteristics in ECT
Electroconvulsive Therapy · Direct Current Electroencephalogram · Ketamine · Spreadind Depression
Bottom Line
View on ClinicalTrials.gov: NCT04022226 ↗Enrolled (actual)
11
Serious AEs
0.0%
Results posted
Oct 2024
Primary outcome: Primary: Number of Participants Assessed for Clinical Efficacy of ECT — 11 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Early Phase 1
- Interventions
- Ketamine (Drug); Methohexital (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of New Mexico
- Primary completion
- Oct 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Assessed for Clinical Efficacy of ECT |
11 | — |
Summary
The investigators will be examining slow-wave characteristics in depressed patients receiving electroconvulsive therapy (ECT) using direct current electroencephalogram (dcEEG) by anesthesia induction agent.
Eligibility Criteria
Inclusion Criteria
- Structured Clinical Interview for DSM-5 will confirm diagnosis of MDD or BPD-depressed (with or without psychotic features
- The clinical indications for ECT including treatment resistance or a need for a rapid and definitive response;
- Hamilton Depression Rating Scale 24-item (HDRS-24) > 21; and
- Age range between 18 and 65 years of age.
Exclusion Criteria
- Defined neurological or neurodegenerative disorder (e.g., history of head injury with loss of consciousness > 5 minutes, epilepsy, Alzheimer's disease);
- Other psychiatric conditions (e.g., schizophrenia, schizoaffective disorder, bipolar disorder)
- Current drug or alcohol use disorder, except for nicotine and marijuana
- Adults unable to consent, pregnant women, prisoner
- Non-English speakers
- Patients that cannot tolerate Methohexital and Ketamine.
Data sourced from ClinicalTrials.gov (NCT04022226). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.